Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice

Critical Reviews in Oncology/Hematology

Volumn 63, Issue 1, 2007, Pages 1-11

  Testart Paillet, Diane ^a,b   Girard, Pascal ^a,b   You, Benoit ^a,b,c   Freyer, Gilles ^a,b,c   Pobel, Christian ^d   Tranchand, Brigitte ^a,b,e  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d Hôpital de Saintes   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; Hematological toxicity; Pharmacokinetics pharmacodynamics models

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; INDISULAM; IRINOTECAN; MELPHALAN; METHOTREXATE; PACLITAXEL; TOPOTECAN;

BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; DRUG EXPOSURE; FEEDBACK SYSTEM; HEMATOPOIETIC CELL; HUMAN; LEUKOPENIA; MATHEMATICAL MODEL; NEUTROPENIA; OVARY CANCER; REVIEW; THROMBOCYTOPENIA;

EID: 34249692520     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.01.005     Document Type: Review

References (75)

1. Ratain M.J., Schilsky R.L., Conley B.A., and Egorin M.J. Pharmacodynamics in cancer therapy. J Clin Oncol 8 (1990) 1739-1753
2. Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D., and Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol 9 (1998) 357-364
3. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 81 (1993) 2844-2853
4. Karlsson M.O., Port R.E., Ratain M.J., and Sheiner L.B. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57 (1995) 325-334
5. Rombout F., Aarons L., Karlsson M., et al. Modelling and simulation in the development and use of anti-cancer agents: an underused tool?. J Pharmacokinet Pharmacodyn 31 (2004) 419-440
6. Masubuchi N., May R.D., and Atsumi R. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colonyforming unit granulocyte/macrophage assay. Clin Cancer Res 10 (2004) 6722-6731
7. Gale R.P., and Testa N.G. Hematopoiesis: long-term effects of chemotherapy and radiation (1988), M. Dekker
8. Silber J.H., Fridman M., DiPaola R.S., Erder M.H., Pauly M.V., and Fox K.R. Firstcycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16 (1998) 2392-2400
9. Link B.K., Budd G.T., Scott S., et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92 (2001) 1354-1367
10. Chatelut E., Delord J.P., and Canal P. Toxicity patterns of cytotoxic drugs. Invest New Drugs 21 (2003) 141-148
11. Mould D.R., Holford N.H., Schellens J.H., et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71 (2002) 334-348
12. Baker S.D., Li J., ten Tije A.J., et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77 (2005) 43-53
13. Huizing M.T., Keung A.C., Rosing H., et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11 (1993) 2127-2135
14. Minami H., Sasaki Y., Watanabe T., and Ogawa M. Pharmacodynamic modeling of the entire time course of leukopenia after a 3-h infusion of paclitaxel. Jpn J Cancer Res 92 (2001) 231-238
15. Minami H., Sasaki Y., Saijo N., et al. Indirectresponse model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64 (1998) 511-521
16. Barbolosi D., Freyer G., Ciccolini J., and Iliadis A. Dosage regimen optimization in cancer chemotherapy using a mathematical model. Bull Cancer 90 (2003) 167-175
17. Goggin T, Jacqmin P, Gieschke R, et al. Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug; 2001.
18. Rivera E., Haim E.M., Fridman M., Frye D., and Hortobagyi G.N. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Res 5 (2003) R114-R120
19. Ozer H. New directions in the management of chemotherapy-induced neutropenia: risk models, special populations, and quality of life. Semin Oncol 30 (2003) 18-23
20. Galpin A.J., and Evans W.E. Therapeutic drug monitoring in cancer management. Clin Chem 39 (1993) 2419-2430
21. Canal P., and Chatelut E. Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship. Bull Cancer 83 (1996) 256-265
22. Brown T., Havlin K., Weiss G., et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9 (1991) 1261-1267
23. Trump D.L., Egorin M.J., Forrest A., Willson J.K., Remick S., and Tutsch K.D. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-h continuous infusion with and without dipyridamole. J Clin Oncol 9 (1991) 2027-2035
24. Gianni L., Kearns C.M., Giani A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13 (1995) 180-190
25. Henningsson A., Sparreboom A., Sandstrom M., et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39 (2003) 1105-1114
26. Kearns C.M., Gianni L., and Egorin M.J. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22 (1995) 16-23
27. Karlsson M.O., Molnar V., Bergh J., Freijs A., and Larsson R. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63 (1998) 11-25
28. Karlsson MO. European cooperation in the field of scientific and technical research: population pharmacodynamic models in cancer chemotherapy (1997), The Office for official publication of the European Communities, Luxembourg p. 117-24
29. Minami H., Ando Y., Sakai S., and Shimokata K. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 13 (1995) 191-199
30. Egorin M.J., Van Echo D.A., Tipping S.J., et al. Pharmacokinetics and dosage reduction of cisdiammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44 (1984) 5432-5438
31. Duffull S.B., and Robinson B.A. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33 (1997) 161-183
32. Arakawa A., Nishikawa H., Suzumori K., and Kato N. Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer. Int J Clin Oncol 6 (2001) 248-252
33. Johan G, Daniel W. Pharmacokinetic and pharmacodynamic data analysis: pharmacodynamic concepts, 3rd ed., 2000.
34. Mager D.E., Wyska E., and Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31 (2003) 510-518
35. Holford N.H., and Sheiner L.B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6 (1981) 429-453
36. van Ruth S., Mathot R.A., Sparidans R.W., Beijnen J.H., Verwaal V.J., and Zoetmulder F.A. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet 43 (2004) 131-143
37. Ratain M.J., Mick R., Schilsky R.L., Vogelzang N.J., and Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9 (1991) 1480-1486
38. Minami H., Ratain M.J., Ando Y., and Shimokata K. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol 39 (1996) 61-66
39. Perez-Urizar J., Granados-Soto V., Flores-Murrieta F.J., and Castaneda-Hernandez G. Pharmacokinetic-pharmacodynamic modeling: why?. Arch Med Res 31 (2000) 539-545
40. Dees E.C., Whitfield L.R., Grove W.R., Rummel S., Grochow L.B., and Donehower R.C. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clin Cancer Res 6 (2000) 3885-3894
41. Wagner J.G. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20 (1968) 173-201
42. Canal P., Gay C., Dezeuze A., et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14 (1996) 2688-2695
43. Egorin M.J., Van Echo D.A., Whitacre M.Y., et al. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46 (1986) 1513-1520
44. Hantel A., Donehower R.C., Rowinsky E.K., et al. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50 (1990) 3284-3288
45. Erlichman C., Moore M., Kerr I.G., et al. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937). Cancer Res 51 (1991) 6317-6322
46. D'Argenio D.Z., and Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9 (1979) 115-134
47. Simonsen L.E., Wahlby U., Sandstrom M., Freijs A., and Karlsson M.O. Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats. Anticancer Res 20 (2000) 1519-1525
48. Ando M., Minami H., Ando Y., et al. Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin Cancer Res 5 (1999) 1690-1695
49. Jodrell D.I., Egorin M.J., Canetta R.M., et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10 (1992) 520-528
50. Levasseur L.M., Slocum H.K., Rustum Y.M., and Greco W.R. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58 (1998) 5749-5761
51. Rosner G.L., and Muller P. Pharmacodynamic analysis of hematologic profiles. J Pharmacokinet Biopharm 22 (1994) 499-524
52. Pobel C., Tranchand B., Ardiet C.J., Parola J.N., and Ménard G. European cooperation in the field of scientific and technical research: population analysis of neutropenic effect of mephalan (1997), The Office for official publication of the European Communities, Luxembourg p. 343-6
53. Fetterly G.J., Tamburlin J.M., and Straubinger R.M. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm Drug Dispos 22 (2001) 251-261
54. Sun Y.N., and Jusko W.J. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87 (1998) 732-737
55. Zamboni W.C., D'Argenio D.Z., Stewart C.F., et al. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7 (2001) 2301-2308
56. Ane C., and Concordet D. Population pharmacokinetics/pharmacodynamics relationships of an anticancer drug. Stat Med 22 (2003) 833-846
57. Friberg L.E., Brindley C.J., Karlsson M.O., and Devlin A.J. Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytidine (DMDC). Eur J Clin Pharmacol 56 (2000) 567-574
58. Savic R, Jonker DM, Kerbusch T, Karlsson MO. Evaluation of a transit compartment model versus a lag time model for describing drug absorption delay; 2004.
59. Friberg L.E., Freijs A., Sandstrom M., and Karlsson M.O. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295 (2000) 734-740
60. Friberg L.E., and Karlsson M.O. Mechanistic models for myelosuppression. Invest New Drugs 21 (2003) 183-194
61. Cox L.A. A biomathematical model of hematotoxicity. Environ Int 25 (1999) 805-817
62. Friberg L.E., Henningsson A., Maas H., Nguyen L., and Karlsson M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20 (2002) 4713-4721
63. Karlsson M.O., Anehall T., Friberg L.E., et al. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol 96 (2005) 206-211
64. Segura C., Bandres E., Troconiz I.F., et al. Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res 21 (2004) 567-573
65. Leger F., Loos W.J., Bugat R., et al. Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76 (2004) 567-578
66. van Kesteren C., Zandvliet A.S., Karlsson M.O., et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23 (2005) 225-234
67. Sandstrom M., Lindman H., Nygren P., Lidbrink E., Bergh J., and Karlsson M.O. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23 (2005) 413-421
68. Sandstrom M., Lindman H., Nygren P., Johansson M., Bergh J., and Karlsson M.O. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58 (2006) 143-156
69. Panetta J.C., Kirstein M.N., Gajjar A.J., Nair G., Fouladi M., and Stewart C.F. A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci 186 (2003) 29-41
70. Krzyzanski W., Ramakrishnan R., and Jusko W.J. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 27 (1999) 467-489
71. Krzyzanski W., Woo S., and Jusko W.J. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J Pharmacokinet Pharmacodyn 33 (2006) 125-166
72. Krzyzanski W., and Jusko W.J. Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J Pharmacokinet Pharmacodyn 29 (2002) 311-337
73. Perez-Ruixo J.J., Kimko H.C., Chow A.T., Piotrovsky V., Krzyzanski W., and Jusko W.J. Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn 32 (2005) 767-793
74. Scholz M., Engel C., and Loeffler M. Modelling human granulopoiesis under poly-chemotherapy with G-CSF support. J Math Biol 50 (2005) 397-439
75. Freyer G., Tredan O., Meille C., et al. Optimal duration of G-CSF prophylaxis after docetaxel (D) + epirubicin (E) in metastatic breast cancer (MBC): prediction using a mathematical model. J Clin Oncol (Meet Abstr) 23 (2005) 2044